PNC Financial Services Group
EGRX

PNC Financial Services Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

PNC Financial Services Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28
Closed -$104 – 4980
2024
Q3 		$104 Hold
28
– – ﹤0.01% 4721
2024
Q2 		$157 Buy
+28
New +$122 ﹤0.01% 4693
2023
Q4 		– Sell
-15
Closed -$237 – 4791
2023
Q3 		$237 Sell
15
-102
-87% -$1.83K ﹤0.01% 4523
2023
Q2 		$2.27K Sell
117
-242
-67% -$5.74K ﹤0.01% 4344
2023
Q1 		$10.2K Sell
359
-267
-43% -$7.93K ﹤0.01% 3811
2022
Q4 		$18.3K Buy
626
+210
+50% +$6.68K ﹤0.01% 3509
2022
Q3 		$11K Sell
416
-380
-48% -$13.9K ﹤0.01% 3744
2022
Q2 		$36K Sell
796
-81
-9% -$3.72K ﹤0.01% 3193
2022
Q1 		$44K Sell
877
-262
-23% -$12.6K ﹤0.01% 3184
2021
Q4 		$58K Sell
1,139
-5
-0.4% -$259 ﹤0.01% 3026
2021
Q3 		$63K Buy
1,144
+304
+36% +$15K ﹤0.01% 2931
2021
Q2 		$36K Buy
840
+54
+7% +$2.23K ﹤0.01% 3235
2021
Q1 		$33K Sell
786
-127
-14% -$5.9K ﹤0.01% 3201
2020
Q4 		$43K Buy
913
+190
+26% +$8.89K ﹤0.01% 2995
2020
Q3 		$31K Buy
723
+205
+40% +$8.97K ﹤0.01% 3009
2020
Q2 		$25K Sell
518
-69
-12% -$3.44K ﹤0.01% 3116
2020
Q1 		$27K Sell
587
-265
-31% -$13.3K ﹤0.01% 2963
2019
Q4 		$51K Sell
852
-20,612
-96% -$1.23M ﹤0.01% 2888
2019
Q3 		$1.22M Sell
21,464
-8,800
-29% -$495K ﹤0.01% 1176
2019
Q2 		$1.69M Buy
30,264
+29,622
+4,614% +$1.54M ﹤0.01% 1078
2019
Q1 		$32K Buy
642
+392
+157% +$17.4K ﹤0.01% 3188
2018
Q4 		$10K Sell
250
-21
-8% -$1.08K ﹤0.01% 3556
2018
Q3 		$19K Hold
271
– – ﹤0.01% 3470
2018
Q2 		$21K Buy
271
+144
+113% +$9.06K ﹤0.01% 3430
2018
Q1 		$7K Sell
127
-1,154
-90% -$67.1K ﹤0.01% 3835
2017
Q4 		$68K Buy
1,281
+151
+13% +$8.4K ﹤0.01% 2772
2017
Q3 		$67K Sell
1,130
-10,139
-90% -$613K ﹤0.01% 2760
2017
Q2 		$889K Buy
11,269
+82
+0.7% +$6.71K ﹤0.01% 1333
2017
Q1 		$928K Sell
11,187
-17,333
-61% -$1.29M ﹤0.01% 1328
2016
Q4 		$2.26M Sell
28,520
-12,482
-30% -$907K ﹤0.01% 935
2016
Q3 		$2.87M Buy
41,002
+28,424
+226% +$1.57M ﹤0.01% 832
2016
Q2 		$488K Buy
12,578
+349
+3% +$14.5K ﹤0.01% 1561
2016
Q1 		$494K Buy
12,229
+3,178
+35% +$202K ﹤0.01% 1564
2015
Q4 		$802K Sell
9,051
-337
-4% -$26.6K ﹤0.01% 1303
2015
Q3 		$694K Buy
9,388
+302
+3% +$25.1K ﹤0.01% 1379
2015
Q2 		$735K Buy
+9,086
New +$592K ﹤0.01% 1415

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

PNC Financial Services Group's EGRX Position: Q4 2024 in Review

PNC Financial Services Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 28 shares — an estimated $104 sold.

PNC Financial Services Group first reported a position in EGRX in Q2 2015 and held it in 36 quarters. The position peaked at $2.87M in Q3 2016. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • PNC Financial Services Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 28 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $104.
  • PNC Financial Services Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 36 quarters.
  • PNC Financial Services Group's Eagle Pharmaceuticals, Inc. position peaked at $2.87M in Q3 2016.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on PNC Financial Services Group's 13F filing for Q4 2024, filed 7 Feb 2025.